About
Andrew Sinclair joined Abingworth in 2008 after working as an equity analyst in the pharmaceutical and biotechnology sectors. He heads the firm's Publics and Late Stage strategies, works across CCD and private investing, and evaluates public company opportunities including VIPE investments. Before Abingworth he was a Senior Equity Analyst and Director at HSBC Global Markets covering mid-cap pharmaceuticals, and previously worked at Credit Suisse and SG Cowen. He holds a PhD in Chemistry and Genetic Engineering from the BBSRC Institute of Plant Science, Norwich, and a BSc in Microbiology from King's College London, and qualified as a chartered accountant with KPMG.
Invests in
Biotech
Experience
- AbingworthPartner, Portfolio Managercurrent2008 — present
Skills & more
From Andrew's professional profile.
Deals · 1
Verona PharmaBoard seat
via Abingworth · filed Jul 2020 · $200.2M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Abingworth
Network5
Investors connected to Andrew in public investor directories — a warm-intro map.